The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope.

IF 2.1 Q3 RHEUMATOLOGY Rheumatology Advances in Practice Pub Date : 2024-07-12 eCollection Date: 2024-01-01 DOI:10.1093/rap/rkae077

Louise Mercer, Abhishek Abhishek, Akhila Kavirayani, Alison Ahmed, Alan Davidson, Amy Foulkes, Claire Jones, Clare Nash, Emily Rose-Parfitt, Emmandeep Dhillon, Genevieve Zabate, Helen Twohig, Hope De Vere, Jennifer Scott, John Reynolds, Julia Holmes, Karen Hartley, Kishore Warrier, Kataryzna Nowak, Kate Parsons, Katie Bechman, Lisa Bray, Madura Adikari, Natasha Wood, Nicola Faithfull, Nicola Gullick, Pratyasha Saha, Rebecca Heaton, Samundeeswari Deepak, Samantha Hider, Sameena Khalid, Sanaa Suleiman Said, Sarah Ryan, Stuart Kyle, Subhra Raghuvanshi, Su-Yin Tan, Vinay Shivamurthy, James Galloway

{"title":"The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope.","authors":"Louise Mercer, Abhishek Abhishek, Akhila Kavirayani, Alison Ahmed, Alan Davidson, Amy Foulkes, Claire Jones, Clare Nash, Emily Rose-Parfitt, Emmandeep Dhillon, Genevieve Zabate, Helen Twohig, Hope De Vere, Jennifer Scott, John Reynolds, Julia Holmes, Karen Hartley, Kishore Warrier, Kataryzna Nowak, Kate Parsons, Katie Bechman, Lisa Bray, Madura Adikari, Natasha Wood, Nicola Faithfull, Nicola Gullick, Pratyasha Saha, Rebecca Heaton, Samundeeswari Deepak, Samantha Hider, Sameena Khalid, Sanaa Suleiman Said, Sarah Ryan, Stuart Kyle, Subhra Raghuvanshi, Su-Yin Tan, Vinay Shivamurthy, James Galloway","doi":"10.1093/rap/rkae077","DOIUrl":null,"url":null,"abstract":"<p><p>This guideline will provide up-to-date, evidence-based recommendations on the safe use of non-biologic DMARDs, also called conventional synthetic DMARDs (csDMARD), across the full spectrum of autoimmune rheumatic diseases. The guideline will update the guideline published in 2017 and will be expanded to include people of all ages. Updated information on the monitoring of DMARDs and vaccinations will be included. The guideline will be developed using the methods and processes described in the British Society for Rheumatology's 'Creating clinical guidelines: our protocol', updated 2023.</p>","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"8 3","pages":"rkae077"},"PeriodicalIF":2.1000,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11239329/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology Advances in Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/rap/rkae077","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

This guideline will provide up-to-date, evidence-based recommendations on the safe use of non-biologic DMARDs, also called conventional synthetic DMARDs (csDMARD), across the full spectrum of autoimmune rheumatic diseases. The guideline will update the guideline published in 2017 and will be expanded to include people of all ages. Updated information on the monitoring of DMARDs and vaccinations will be included. The guideline will be developed using the methods and processes described in the British Society for Rheumatology's 'Creating clinical guidelines: our protocol', updated 2023.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

传统合成改变病情抗风湿药物的处方和监测：英国风湿病学会指南范围。

本指南将就非生物DMARDs（也称为传统合成DMARDs（csDMARD））在自身免疫性风湿病全病程中的安全使用提供最新的循证建议。该指南将更新2017年发布的指南，并将扩展至所有年龄段的人群。其中还将包括有关 DMARDs 监测和疫苗接种的最新信息。该指南将采用英国风湿病学会 "创建临床指南：我们的协议"（2023 年更新）中描述的方法和流程来制定。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊